ArticleGut pathogens2026
Microbiome/transforming growth factor-β axis as a diagnostic and therapeutic target for MASLD in Egyptian patients.
Article in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading cause of chronic hepatic disorders worldwide. Gut microbiome dysbiosis influences MASLD pathogenesis via the gut–liver axis. This study investigated gut microbiome alterations, biochemical markers, and their diagnostic potential in MASLD. A case control study included 60 Egyptian adults (30 MASLD patients, 30 healthy controls) who underwent comprehensive biochemical profiling and quantitative real-time polymerase chain reaction (qRT-PCR) analysis of selected gut microbiota from fecal samples. Antioxidant biomarkers, including superoxide dismutase (SOD) and malondialdehyde (MDA), were measured spectrophotometrically, while mRNA expression of nuclear factor erythroid 2-related factor 2 (NRF2), transforming growth factor-beta (TGF-β), and signal transducer and activator of transcription 3 (STAT3) was assessed by reverse transcription PCR (RT-PCR). The fibrosis index (FIB-4) was calculated, and diagnostic accuracy was evaluated using receiver operating characteristic (ROC) curves. MASLD patients displayed marked microbiome dysbiosis, with significant enrichment of Bacteroides (p < 0.001) and depletion of Bifidobacterium (p < 0.005). TGF-β expression was significantly elevated (p < 0.001) and demonstrated excellent diagnostic performance (area under the curve [AUC] = 0.956; sensitivity = 100%; specificity = 83.3%). MDA, FIB-4, and NRF2 showed moderate accuracy, while Bacteroides (AUC = 0.744) and Bifidobacterium (AUC = 0.683) also provided discriminatory value. Bacteroides correlated positively with total cholesterol, whereas Bifidobacterium correlated inversely. Collectively, elevated TGF-β, increased Bacteroides, and reduced Bifidobacterium highlight promising diagnostic and therapeutic targets in MASLD. These findings emphasize the mechanistic role of the gut–liver axis and support microbiome-informed roles for early detection and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.